{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Methods. This was a randomized, double-blind, parallel-group study"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Methods. This was a randomized, double-blind, parallel-group study"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients experiencing pain of at least moderate intensity on the day after surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "dexketoprofen/tramadol 25 mg/75 mg fixed-dose combination vs dexketoprofen (25 mg) and tramadol (100 mg)"
      },
      "Objective": {
        "score": 1,
        "evidence": "The aim was to evaluate the analgesic efficacy and safety of the dexketoprofen/tramadol 25 mg/75 mg fixed-dose combination"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary end point was the mean sum of the pain intensity difference values throughout the first 8 h (SPID 8 )"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 2,
        "evidence": "double-blind"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Overall, 641 patients, mean age 62 (range 29\u201380) yr, were analysed"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "641 patients, mean age 62 (range 29\u201380) yr, were analysed"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "mean ( sd ) values of SPID 8 were 247 (157) for dexketoprofen/tramadol, 209 (155) for dexketoprofen, 205 (146) for tramadol, and 151 (159) for placebo. The primary analysis confirmed the superiority of the combination over dexketoprofen 25 mg ( P =0.019; 95% confidence interval 6.4\u201373) and tramadol 100 mg ( P =0.012; 95% confidence interval 9.5\u201376)"
      },
      "Harms": {
        "score": 1,
        "evidence": "The incidence of adverse drug reactions was low and similar among active treatment groups"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "EudraCT 2012-004548-31 ( https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004548-31 ); ClinicalTrials.gov NCT01902134 ( https://www.clinicaltrials.gov/ct2/show/NCT01902134?term=NCT01902134&rank=1 )"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 18,
    "max_score": 25
  },
  "model": "gpt-4o"
}